Results from a phase II study of Vibecotamab, a CD123xCD3 bispecific T-cell engager (TCE) antibody, were reported in 37 patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) following hypomethylating agent (HMA) treatment failure, and MRD-positive AML. This evidence concerns the gene TBXT and myelodysplastic syndrome.